Of all the cases of economic espionage charged by the DOJ's National Security Division since 2012, more than 80% of them implicated China.World Politicsread more
"Whilst there is a big dispute at the moment, I think there's also potential for resolution," UBS chairman Axel Weber says of the U.S.-China trade negotiations.World Economyread more
Cryptocurrency fans will hope the futures contracts, which are federally regulated, can provide some much-needed legitimacy to bitcoin.Cryptocurrencyread more
Despite mixed fan and critic reactions to the final season of "Game of Thrones," the eight-season epic took home the top prize in the drama category at the Emmy Awards on...Entertainmentread more
There are alternative financial centers and investors can turn to Singapore, Tokyo or Shanghai if Hong Kong doesn't "shape up," says the founder and chairman of Citic Capital.Asia Economyread more
The Kingdom and oil and gas industry have been slow to shore up defenses, raising red flags about the possibility of longer term fall-out in the region.Technologyread more
Tensions between South Korea and Japan may ultimately disrupt the high-end tech sectors, says Heenam Choi, CEO at South Korea's sovereign wealth fund.Traderead more
On Sunday, the 71st Primetime Emmy Awards honored the best comedies, dramas, limited and variety series from the last year.Entertainmentread more
U.S. President Donald Trump's national security advisor said on Sunday that White House Asia policy adviser Matt Pottinger would become his top deputy.Politicsread more
Removing Neumann is a difficult decision for Son, who has long believed in WeWork and Neumann's vision to quickly expand the company.Technologyread more
Datadog went public on Thursday and instantly hit a $10 billion valuation, becoming the fourth cloud software debut to reach that level this year.Technologyread more
(Adds details on approval, lymphoma)
June 10 (Reuters) - The U.S. Food and Drug Administration granted accelerated approval to Roche Holding AG's combo lymphoma treatment for previously treated patients, the company said on Monday.
The drug, Polivy, is used in combination with Rituxan and a chemotherapy agent to treat an aggressive form of the disease.
The combo is used to treat adults, who have received at least two prior therapies for relapsed or refractory form of non-Hodgkin's lymphoma (NHL).
Roche estimates that nearly 25,000 new cases to be recorded in the United States this year.
NHL, which is one of the most common cancers in the United States, accounts for about 4% of all types of cancers, according to the American Cancer Society.
Continued approval for the treatment may depend on data from a confirmatory trial, Roche said.
The FDA's accelerated approval program allows conditional approval of a medicine that fills an unmet medical need for a serious condition. (Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Anil D'Silva and James Emmanuel)